Inclusion Criteria:

          -  Participants with HR-positive HER2-negative advanced or metastatic breast cancer
             (received at least two prior lines in the advanced or metastatic setting including one
             prior line of combined CDK4/6 inhibitor and endocrine therapy and no more than two
             prior lines of cytotoxic chemotherapy)

          -  Participants with locally recurrent/advanced or metastatic TNBC who have received up
             to 2 prior lines of chemotherapy in the advanced or metastatic setting

          -  Participants with advanced platinum resistant epithelial ovarian cancer
             (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) (histologically or
             cytologically proven) who have received up to 3 prior lines of therapy

          -  Participants with cytological diagnosis of advanced/metastatic SCLC

          -  Participants with or cytological diagnosis of advanced/metastatic NSCLC

          -  Participants entering the study in the expansion cohort have at least one measurable
             lesion as defined by RECIST version 1.1 that has not been previously irradiated

          -  Performance Status 0 or 1

          -  Adequate bone marrow, hematological, kidney and liver function

          -  Resolved acute effects of any prior therapy to baseline severity

        Exclusion Criteria:

          -  Participants with known symptomatic brain metastases requiring steroids

          -  Participants with any other active malignancy within 3 years prior to enrollment

          -  Major surgery within 3 weeks prior to study entry

          -  Radiation therapy within 3 weeks prior to study entry.

          -  Systemic anti cancer therapy within 4 weeks prior to study

          -  Prior irradiation to >25% of the bone marrow

          -  Participants with active, uncontrolled bacterial, fungal, or viral infection,
             including HBV, HCV, and known HIV or AIDS related illness

          -  COVID-19/SARS-CoV2

          -  Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may
             affect participant safety or interpretation of study results

          -  Any of the following in the previous 6 months: myocardial infarction, long QT
             syndrome, Torsade de Pointes, arrhythmias, serious conduction system abnormalities,
             unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, New York
             Heart Association class III or IV, cerebrovascular accident, transient ischemic
             attack, symptomatic pulmonary embolism, and/or other clinical significant episode of
             thrombo embolic disease.

          -  Anticoagulation with vitamin K antagonists or factor Xa inhibitors is not allowed.

          -  Hypertension that cannot be controlled by medications

          -  Participation in other studies involving investigational drug(s) within 2 weeks prior
             to study entry.

          -  Known or suspected hypersensitivity to active ingredient/excipients in PF 07104091.

          -  Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular
             disease or previous gastric resection or lap band surgery.

          -  Participants with advanced/metastatic, symptomatic, visceral spread, that are at risk
             of life threatening complications in the short

          -  Participants with an indwelling catheter that has an external component such as those
             used for drainage of effusion(s) or central venous catheter that is externally

          -  Previous high dose chemotherapy requiring stem cell rescue

          -  Known abnormalities in coagulation such as bleeding diathesis, or treatment with
             anticoagulants precluding intramuscular injections of goserelin (if applicable).

          -  Current use or anticipated need for food or drugs that are known strong CYP3A4/5 or
             UGT1A9 inhibitors or inducers

          -  Current use or anticipated need for drugs that are known sensitive UGT1A1 substrates
             with narrow therapeutic

          -  Serum pregnancy test positive at screening

          -  Other medical or psychiatric condition